Related Experiment Video

Updated: Jul 16, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantable defibrillators and beta-blockers in patients with left ventricular dysfunction: economic, ethical, and

Marc T Silver1

  • 1Raleigh Cardiology Associates, Raleigh, NC 27610-1231, USA. marctsilvermd@msn.com

American Heart Journal
|March 31, 2007
PubMed

Insights

Primary prevention implantable cardioverter defibrillators and beta-blockers offer benefits for heart failure patients with left ventricular dysfunction. This article explores the economic, ethical, and legal considerations of these treatments.

Area of Science:

  • Cardiology
  • Medical Ethics
  • Health Economics

Background:

  • Left ventricular dysfunction is a significant risk factor for sudden cardiac death in heart failure patients.
  • Primary prevention implantable cardioverter defibrillators (ICDs) and beta-blockers are established therapies for managing this risk.
  • Understanding the broader implications of these treatments is crucial for optimal patient care.

Purpose of the Study:

  • To re-evaluate the use of primary prevention ICDs and beta-blockers in heart failure patients with left ventricular dysfunction.
  • To analyze the economic, ethical, and legal principles associated with these therapies.
  • To encourage a novel perspective on treatment decisions in heart failure management.

Main Methods:

  • Review of landmark clinical trials: MADIT II, SCD-HeFT, and COMET.
  • Analysis of treatment data through the lens of economic, ethical, and legal frameworks.
  • Discussion of the implications for clinical practice and patient outcomes.

Main Results:

  • Landmark trials provide evidence supporting the efficacy of ICDs and beta-blockers in specific heart failure populations.
  • Economic analyses highlight cost-effectiveness considerations for widespread implementation.
  • Ethical and legal discussions address patient autonomy, resource allocation, and professional responsibility.

Conclusions:

  • The decision to use primary prevention ICDs and beta-blockers requires a comprehensive evaluation beyond clinical efficacy.
  • Economic, ethical, and legal factors significantly influence treatment guidelines and accessibility.
  • A multidisciplinary approach is essential for informed decision-making in heart failure management.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...